Drug intelligence / Profile preview

E-612

Development stage: Preclinical
Lead developer: Palleon Pharmaceuticals
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

E-612 is a bi-sialidase antibody-enzyme fusion protein developed by Palleon Pharmaceuticals for the treatment of autoimmune diseases. It is engineered using the company's proprietary EAGLE (Enzyme-Antibody Glycan Ligand Editing) platform. The drug is designed to enzymatically remove terminal sialic acids from cell-surface glycans, which act as immune-modulating signals. By desialylating these glycans, E-612 aims to disrupt the 'glyco-immune checkpoint' and restore immune homeostasis in patients with autoimmune disorders. As of the latest reports, the program is in the lead optimization stage of preclinical development.

Targets

SA (Sialic acid)

Beyond the preview

Go deeper on E-612.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-612.

Explore the full profile